US 12,258,411 B2
Anti-CCR8 antibodies and uses thereof
Nathan William Pierce, Mountain View, CA (US); Agnieszka Kielczewska, Vancouver (CA); Wentao Chen, Thousand Oaks, CA (US); Olivier Nolan-Stevaux, Millbrae, CA (US); Darren L. Bates, Oak Park, CA (US); Lisa Winkel, Munich (DE); Christoph Dahlhoff, Geretsried (DE); Tobias Raum, Eurasburg (DE); Claudia Bluemel, Munich (DE); and Jonas Karl-Josef Honer, Munich (DE)
Assigned to AMGEN INC., Thousand Oaks, CA (US); and AMGEN RESEARCH (MUNICH) GmbH, Munich (DE)
Filed by AMGEN INC., Thousand Oaks, CA (US); and AMGEN RESEARCH (MUNICH) GmbH, Munich (DE)
Filed on Jun. 2, 2022, as Appl. No. 17/831,398.
Claims priority of provisional application 63/236,551, filed on Aug. 24, 2021.
Claims priority of provisional application 63/197,271, filed on Jun. 4, 2021.
Prior Publication US 2022/0403037 A1, Dec. 22, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 29 Claims
 
1. An antibody that binds to human C—C chemokine receptor type 8 (CCR8), the antibody comprising:
(a) a heavy chain complementarity-determining region (HCDR) 1 amino acid sequence comprising SEQ ID NO: 839;
(b) an HCDR2 amino acid sequence comprising SEQ ID NO: 840,
(c) an HCDR3 amino acid sequence comprising SEQ ID NO: 841,
(d) a light chain complementarity-determining region (LCDR) 1 amino acid sequence comprising SEQ ID NO: 842,
(e) an LCDR2 amino acid sequence comprising SEQ ID NO: 843, and
(f) an LCDR3 amino acid sequence comprising SEQ ID NO: 844.